X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Natco Pharma with AANJANEYA LIFECARE - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NATCO PHARMA vs DR. DATSONS LABS - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NATCO PHARMA DR. DATSONS LABS NATCO PHARMA/
DR. DATSONS LABS
 
P/E (TTM) x 30.7 -10.9 - View Chart
P/BV x 23.2 0.2 14,306.0% View Chart
Dividend Yield % 0.5 0.0 -  

Financials

 NATCO PHARMA   DR. DATSONS LABS
EQUITY SHARE DATA
    NATCO PHARMA
Mar-14
DR. DATSONS LABS
Mar-14
NATCO PHARMA/
DR. DATSONS LABS
5-Yr Chart
Click to enlarge
High Rs877126 698.2%   
Low Rs42431 1,370.6%   
Sales per share (Unadj.) Rs223.4133.0 168.0%  
Earnings per share (Unadj.) Rs31.10.2 20,491.6%  
Cash flow per share (Unadj.) Rs40.36.6 609.5%  
Dividends per share (Unadj.) Rs5.000-  
Dividend yield (eoy) %0.80-  
Book value per share (Unadj.) Rs219.5128.8 170.4%  
Shares outstanding (eoy) m33.0731.66 104.5%   
Bonus/Rights/Conversions PAFCCB-  
Price / Sales ratio x2.90.6 494.6%   
Avg P/E ratio x20.9516.1 4.1%  
P/CF ratio (eoy) x16.111.8 136.3%  
Price / Book Value ratio x3.00.6 487.6%  
Dividend payout %16.10-   
Avg Mkt Cap Rs m21,5042,477 868.0%   
No. of employees `000NANA-   
Total wages/salary Rs m1,12856 2,013.8%   
Avg. sales/employee Rs ThNMNM-  
Avg. wages/employee Rs ThNMNM-  
Avg. net profit/employee Rs ThNMNM-  
INCOME DATA
Net Sales Rs m7,3894,211 175.5%  
Other income Rs m16779 212.3%   
Total revenues Rs m7,5564,289 176.2%   
Gross profit Rs m1,793569 315.4%  
Depreciation Rs m304204 148.9%   
Interest Rs m366430 85.1%   
Profit before tax Rs m1,29013 10,155.9%   
Minority Interest Rs m460-   
Prior Period Items Rs m0-2 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m3096 5,060.7%   
Profit after tax Rs m1,0275 21,404.2%  
Gross profit margin %24.313.5 179.7%  
Effective tax rate %23.948.0 49.8%   
Net profit margin %13.90.1 12,197.0%  
BALANCE SHEET DATA
Current assets Rs m3,6816,852 53.7%   
Current liabilities Rs m3,1236,711 46.5%   
Net working cap to sales %7.63.3 225.7%  
Current ratio x1.21.0 115.5%  
Inventory Days Days89161 55.6%  
Debtors Days Days59318 18.4%  
Net fixed assets Rs m7,6853,673 209.2%   
Share capital Rs m331317 104.5%   
"Free" reserves Rs m6,6703,761 177.3%   
Net worth Rs m7,2594,078 178.0%   
Long term debt Rs m9551,671 57.2%   
Total assets Rs m11,95712,633 94.7%  
Interest coverage x4.51.0 439.2%   
Debt to equity ratio x0.10.4 32.1%  
Sales to assets ratio x0.60.3 185.4%   
Return on assets %11.73.4 338.5%  
Return on equity %14.20.1 12,023.4%  
Return on capital %20.77.7 270.1%  
Exports to sales %39.422.9 171.9%   
Imports to sales %5.714.3 39.9%   
Exports (fob) Rs m2,908964 301.6%   
Imports (cif) Rs m421602 70.0%   
Fx inflow Rs m3,445964 357.4%   
Fx outflow Rs m703607 115.8%   
Net fx Rs m2,743357 768.5%   
CASH FLOW
From Operations Rs m1,4401,345 107.1%  
From Investments Rs m-1,089-2,256 48.3%  
From Financial Activity Rs m-353-1,200 29.4%  
Net Cashflow Rs m-1-2,111 0.1%  

Share Holding

Indian Promoters % 52.0 4.5 1,148.8%  
Foreign collaborators % 1.5 0.0 -  
Indian inst/Mut Fund % 7.8 0.0 -  
FIIs % 16.6 1.4 1,231.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 26.0 94.1 27.6%  
Shareholders   25,395 20,807 122.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NATCO PHARMA With:   FRESENIUS KABI ONCO.  DIVIS LABORATORIES  AUROBINDO PHARMA  DISHMAN PHARMA  FDC LTD.  

Compare NATCO PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex, Nifty Close at Record Highs; Bank & Realty Stocks Rally(Closing)

After opening the day marginally higher, Indian share markets extended gains in the afternoon session after the government decided to cut tax rates on certain products and services.

Related Views on News

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

Did GST and Notebandi Help? Sherlock Holmes Finds Out...(The 5 Minute Wrapup)

Jan 13, 2018

Discussions with my cousin helped me understand the situation on Ground Zero - after the demonetization and GST upheaval. Here's what that means for listed companies...

Resolutions for 2018 - by others(The Honest Truth)

Jan 8, 2018

Ten quirky new year resolutions. Guess by whom?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

NATCO PHARMA SHARE PRICE


Jan 19, 2018 (Close)

TRACK NATCO PHARMA

  • Track your investment in NATCO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NATCO PHARMA - UNICHEM LAB COMPARISON

COMPARE NATCO PHARMA WITH

MARKET STATS